Pms50 - Cost-Effectiveness Analysis of Apremilast in the Treatment of Psoriatic Arthritis (Psa) in the Slovak Republic and Slovenia

Value in Health- United Kingdom

doi 10.1016/j.jval.2018.09.1764

Full Text

Abstract

Available in

Categories

Occupational Health

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis

Rheumatology and Therapy

English

Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States

Value in Health

Occupational Health

English

Cost-Effectiveness of Certolizumab Pegol in the Treatment of Active Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis in Romania

Value in Health

Occupational Health

English

Cost Per Responder of Apremilast Versus Etanercept and Adalimumab in Patients With Active Psoriatic Arthritis

Value in Health

Occupational Health

English

Pms54 - Cost-Effectiveness Analysis of Etanercept as First Line of Treatment in Colombian Patients With Psoriatic Arthritis

Value in Health

Occupational Health

English

Pss13 - Budget Impact Analysis of Apremilast in Patients With Active Psoriatic Arthritis in Greece

Value in Health

Occupational Health

English

PND34 Cost-Utility Analysis of Lacosamide Adjunctive Therapy in the Treatment of Patients With Refractory in the Slovak Republic

Value in Health

Occupational Health

English

The Cost-Effectiveness of Alternative Treatment Sequences in Rheumatoid Arthritis

Value in Health

Occupational Health

English

Treatment to Target in Psoriatic Arthritis With Apremilast: Probability of Achieving Targets and Comprehensive Control of Disease Manifestations

Arthritis Care and Research

English